Differentiation and Tolerance of CD4
            <sup>+</sup>
            T Lymphocytes

Ak, Abbas; Vl, Perez; L, Van Parijs; Rc, Wong

doi:10.1002/9780470514849.ch2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

2022

Publication Types

Select...

Book3

Article2

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripheral tolerance is achieved by various mechanisms including T cell ignorance, deletion of activated/effector T cells, anergy induction, deletion by apoptosis, and the suppressive actions of regulatory T lymphocytes (Treg) [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

CTLA-4Ig: Uses and Future Directions

Ben‐Shoshan¹

2009

IAD

View full text Add to dashboard Cite

Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a member of the CD28 receptor family. Blocking CD28 interaction with its ligands through the use of CTLA-4Ig might contribute to better control of dysregulated immune response processes. The ligands binding to CTLA-4 are the B7 family members, B7-1 (CD80) and B7-2 (CD86). CTLA-4Ig is now a Food and Drug Administration-approved drug for use treating patients with Rheumatoid arthritis (RA) but its use is explored also in other autoimmune diseases, transplantation as well as allergic diseases. Patents related to CTLA-4 function as well as possible clinical applications are discussed in this paper.

show abstract

Section: Introductionmentioning

confidence: 99%